Business Wire

Surfin Meta Digital Technology Pte Ltd (“Surfin”) Welcomes John Quelch and John Fennell to its Board of Directors

14.4.2023 05:00:00 EEST | Business Wire | Press release

Share

Surfin group of companies (“Surfin Group”), headquartered in Singapore, a leading provider of digital financial solutions for under-serviced clients in emerging markets, is pleased to announce the appointments of John Quelch and John Fennell to its Board of Directors. These two highly experienced professionals bring an extensive wealth of expertise in marketing, global business strategy, risk management, and leadership to the Surfin Group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005053/en/

Dr. Quelch is a highly respected expert in international strategy, global marketing, and ESG with more than five decades of experience serving as a non-executive director of public companies in the USA and UK. As a member of Surfin’s board of directors, Quelch brings a wealth of experience in corporate governance, strategic planning, and ESG initiatives. He has served on the boards of several important public companies, including Alere, Aramark, Gentiva Health Services, Pepsi Bottling Group, and WPP. He has also served as Dean of both the China Europe International Business School and London Business School. "I am excited to join Surfin Group's board of directors and to work with the company's talented leadership team," said Quelch. "Surfin Group is at the forefront of providing inclusive finance through its innovative digital solutions to emerging markets, and I look forward to contributing my expertise to support the company's growth and success." Quelch was awarded the CBE (Commander of the Order of the British Empire).

John Fennell, a seasoned risk management professional, will bolster Surfin Group's efforts to optimize its risk and control environment as the company looks to expand its digital financial technology offerings, including robo-advisor wealth management and digital security trading for Millennials and Gen Z in developing countries. Mr. Fennell has previously served as Chief Risk Officer of the Options Clearing Corporation, overseeing risk at multiple organizations responsible for systemic resilience of financial markets. His participation in serving on the committees of World Federation of Exchanges and CCP12 will prove invaluable as the company seeks to develop cross-border trading products and engage with local exchanges. Fennell shared his thoughts on the appointment, saying, "I'm thrilled to be part of Surfin Group's mission to promote financial inclusion and innovation in developing countries. I look forward to applying my risk management expertise to ensure the company's continued success and growth."

Yanan Wu, CFA, Ph.D, Chairman of Surfin Group, expressed the company's enthusiasm about the appointments of Dr. Quelch and Mr. Fennell: "We are thrilled to welcome both John Quelch and John Fennell to our Board of Directors. We are confident that their combined expertise and experience will significantly contribute to our growth and help us achieve our ambitions of becoming a forefront leader in digital financial technologies, promoting transparency, innovation, and financial inclusion in developing countries."

About Surfin Group

Surfin Group, headquartered in Singapore, is a leading provider of digital financial solutions for under-serviced clients in emerging markets. The group is committed to providing innovative digital solutions to its clients, with a focus on transparency, inclusion, innovation, and compassion. For more information, please visit www.surfin.sg.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Daju Gu, Board Secretary
Email: daju.gu@surfin.sg
Phone: +1 416 414 3426

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye